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INTRODUCTION
Thyroid goiters are very common medical problems; how-
ever, the mechanism by which they develop are not fully un-
derstood. In about 4.1% of patients with goiter and in areas
with endemic thyroid goiter up to 20% develop thyroid car-
cinomas. This prevalence is as high as that reported in pati-
ents with thyroid nodules (1, 2). Therefore, elucidation of the
mechanism of goitrogenesis may be very important for the
prevention and improved treatment of goiter. Many growth
factors are thought to be involved in goitrogenesis; elevated
thyroid stimulating hormone (thyrotropin, TSH) levels are
considered to play an important role in goitrogenesis.
TSH is the major regulator of thyroid hormone synthesis and
secretion. It is best known for actions that are mediated by
cyclic 3, 5′ -adenosine monophosphate (cyclic AMP). How-
ever, it regulates many other signaling pathways via expres-
sion of a number of genes. These pathways regulate iodide
uptake and de novo synthesis and release of thyroid hormone
and cell proliferation (3-5). TSH has been shown to stimu-
late cell cycle progression and proliferation in cooperation
with insulin or insulin-like growth factor-1 (IGF-1) in vari-
ous thyrocyte culture systems including rat thyroid cell lines
(FRTL-5) and in primary cultures of rat, dog, sheep, and
human thyroid cells (1, 2, 6, 7). In FRTL-5 cells, it is well-
known that a 12- to 24-hr pre-incubation with TSH strongly
amplifies DNA synthesis when insulin or IGF-1 is added to
the culture (3-5). Thyrocytes have been observed to respond
differently depending on the growth factor added or pre-con-
ditioning. Therefore, pre-conditioning with TSH may play
an important role in the regulation of cell proliferation ini-
tiated by other growth factors.
In order to better understand the genes involved we cul-
tured rat thyrocytes and examined the genes regulated by
TSH, IGF-1, and insulin using the microarray technology.
cDNA microarrays are known to be powerful tools for the
study of hormonal effects on cellular metabolism and gene
regulation on the genomic scale; this technique enables simul-
taneous measurement and comparison of the expression lev-
els of thousands of genes (8). We anticipate that this study
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Microarray Analysis of Thyroid Stimulating Hormone, Insulin-Like
Growth Factor-1, and Insulin-Induced Gene Expression in FRTL-5
Thyroid Cells
To determine which genes are regulated by thyroid stimulating hormone (thy-
rotropin, TSH), insulin and insulin-like growth factor-1 (IGF-1) in the rat thyroid, we
used the microarray technology and observed the changes in gene expression.
The expressions of genes for bone morphogenetic protein 6, the glucagon receptor,
and cyclin D1 were increased by both TSH and IGF-1; for cytochrome P450,
2c37, the expression was decreased by both. Genes for cholecystokinin, glu-
curonidase, beta, demethyl-Q 7, and cytochrome c oxidase, subunit VIIIa, were
up-regulated; the genes for ribosomal protein L37 and ribosomal protein L4 were
down-regulated by TSH and insulin. However, there was no gene observed to be
regulated by all three: TSH, IGF-1, and insulin molecules studied. These findings
suggest that TSH, IGF-1, and insulin stimulate different signal pathways, which
can interact with one another to regulate the proliferation of thyrocytes, and there-
by provide additional influence on the process of cellular proliferation.
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may provide important information regarding the underly-
ing mechanism involved in goitrogenesis. 
MATERIALS AND METHODS
Cell culture
A fresh subclone of FRTL-5 rat thyroid cells was obtained
from the Interthyr Research Foundation (Dr. Kohn, Ohio
University, OH, U.S.A.). The doubling time of these cells
was 36±6 hr when cultured in the presence of TSH; they
did not proliferate in the absence of TSH. Cells were grown
in 6H medium, which consisted of Coon’s modified F-12
medium supplemented with 5% calf serum, 1 mM none-
ssential amino acids, and a mixture of six hormones: bovine
TSH (10 U/L), insulin (10 mg/L), hydrocortisone (0.4 mg/
L), human transferrin (5 mg/L), glycyl-L-histidyl-L-lysine
acetate (10  g/L), and somatostatin (10  g/L). Prior to the
experiments and after the cells were about 80% confluent,
the cells were grown for seven days in 5H medium depleted
of TSH. Then they were grown in 3H medium (hydrocorti-
sone, human transferrin, and glycyl-L-histidyl-L-lysine acetate)
for 24 hr prior to treatment with TSH, insulin, or IGF-1.
TSH, insulin, and IGF-I were purchased from Sigma
Chemical Co. (St. Louis, MO, U.S.A.). All tissue culture
reagents were purchased from Life Technologies (Gaithers-
burg, MD, U.S.A.), and all other materials were from Sigma,
unless otherwise indicated.
Microarray analysis
Total RNA from FRTL-5 cells was extracted using the Tri-
zol reagent (Invitrogen, San Diego, CA, U.S.A.), according
to the protocol described by the manufacturer and quanti-
fied by spectrophotometry (Beckman, Fullerton, CA, U.S.A.).
Gene expression chips (GeneTrack
� cDNA microarray
RSVC321, GenomicTree, Tajeon, Korea) containing 5,000
rat genes were used to investigate changes in gene expres-
sion. The list of genes on the chips is available at the inter-
net address www.genomictree.com. For the microarray hyb-
ridizations, RNA was labeled with one of the fluorescent dyes
Cy3 or Cy5 (Amersham Bioscience, Piscaraway, NJ, U.S.A.).
Labeled Cy3 and Cy5 cDNA probes were cleaned with a
Qiaquick nucleotide removal kit (Qiagen). The purified
probes were dried and resuspended in 40  L of hybridiza-
tion buffer containing 5×sodium chloride, sodium citrate
buffer (SSC), 10% sodium dodecyl sulphate (SDS), 20  g
Cot-1 DNA (Gibco BRL), 20  g poly A RNA (Promega,
Madison, WI, U.S.A.), and 20  g yeast tRNA (Gibco BRL).
Common
symbol
Gene name Ratio
Upregulated
Genes associated with binding
Coronin, actin binding protein 1A Coro1a 1.553
Actinin Actn1 1.522
Genes associated with catalytic activity
Brain-enriched guanylate kinase Begain 2.153
Mitochondrial processing peptidase beta Pmpcb 1.988
Homeodomain-interacting protein kinase 3 Hipk3 1.870
Peptidylprolyl isomerase A Ppia 1.839
Proteasome subunit, alpha type 1 Psma1 1.823
Brain acyl-CoA hydrolase Bach 1.575
Carbonyl reductase 1 Cbr1 1.258
Genes associated with transporter activity
ATPase Na+/K+ transporting beta 1  Atp 1b1 3.498
polypeptide
Hydroxyacyl-Coenzyme A dehydroge- Hadhb 1.960
nase/3-ketoacyl-Coenzyme A thiolase/
enoyl-Coenzyme A hydratase, beta subunit
Cytochrome c oxidase, subunit VIIIa  Cox8a 1.905
Acyl-CoA oxidase RATACOA1 1.559
Carbonyl reductase 1 Cbr1 1.258
Unclassified
Activity-dependent neuroprotective protein Adnp 3.538
Cholecystokinin Cck 2.523
Calnexin Canx 2.231
Bone morphogenetic protein 6 Bmp6 2.061
Table 1. Genes that were up- and down-regulated by thyrotropin
Common
symbol
Gene name Ratio
Demethyl-Q 7 Coq7 1.855
B-cell translocation gene 2, anti-proliferative Btg2 1.722
Plysia ras-related homolog A2 Arha2 1.644
Vesicle transport-related RA410 1.535
Myotrophin Mtpn 1.432
Neurogranin Nrgn 1.421
Nucleophosmin 1 Npm1 1.305
Cadherin 1 Cdh1 1.177
Downregulated
Genes associated with binding
Nuclear pore glycoprotein 62 Nup62 0.525
Genes associated with catalytic activity
Nucleoside phosphorylase Np 0.213
Tyrosine 3-monooxygenase/tryptophan 5- Ywhah 0.601
monooxygenase activation protein, 
eta polypeptide
Genes associated with motor activity
Microtubule-associated protein, RP/EB family, Mapre1 0.374
member 1
Genes associated with signal transducer activity
Prostaglandin E receptor 4 Ptger4 0.275
Unclassified
2,3-oxidosqualene: lanosterol cyclase Lss 0.334
Upregulated by 1,25-dihydroxyvitamin D3 Vdup1 0.450
Preoptic regulatory factor-2 PROF-2 0.501
Growth arrest and DNA-damage-inducible  Gadd45 0.527
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Hybridization was performed at 65℃ overnight. Then the
microarray slide was washed with distilled water and spin-
dried. 
Fluorescent intensities of the printed cDNA targets were
measured using a GenePix Pro 3.0 microarray scanner (Axon
Instruments, Foster City, CA, U.S.A.), and the log ratios of
fluorescent intensities within each of the slides were adjust-
ed for data normalization (9). Images were analyzed using
GenePix Pro 3.0 (Axon Instruments, Foster City, CA, U.S.A.)
and gene expression pattern clustering (hierarchical cluster-
ing and SOM) was performed using the programs Cluster
version 2.12 and TreeView version 1.50.
Data analysis
Data acquisition was performed with GenePix Pro 3.0
software (Axon Instruments). Each gene had six ratio values,
and statistical analysis was performed using the t-test. Nor-
malized and averaged fluorescence ratios of genes were used
to calculate the increase and decrease of expression in treated
samples compared with control samples. The expression of a
gene was considered changed when the difference between
means was significant (p<0.05).
RESULTS
TSH-induced gene expression
TSH treatment for 24 hr increased expression of some genes.
Those that were up-regulated and down-regulated by thyro-
tropin are listed in Table 1. The expression of genes for brain-
enriched guanylate kinase, ATPase Na+/K+ transporting
beta 1 polypeptide, activity-dependent neuroprotective pro-
tein, cholecystokinin, calnexin, and bone morphogenetic pro-
tein 6 was more than doubled; the expression of genes for
nucleoside phosphorylase, microtubule-associated protein,
and prostaglandin E receptor 4, 2, 3-oxidosqualene was reduc-
ed by more than half.
Changes of gene expression by TSH according to time 
We treated the cells with TSH for 6, 12, 24, and 48 hr and
observed gene expression and its variation, according to time.
The features of gene expression change are presented in Table
2. The presence of a cluster group was categorized according to
the gene expression pattern by clustering analysis. Gene ex-
pression was noted to be increased at each of the times analyzed
and thereafter normalized. Genes in group 1, 2, 3, and 4 had
maximum expression at 6, 12, and 24 hr, and at 24 and 48 hr. 
As noted in Table 2, TSH appears to stimulate a different
gene expression pattern in thyrocytes according to time; the
effects may be at their maximum within 24 hr and thereafter
decrease with time. 
Insulin or IGF-1 induced changes of gene expression
We also observed changes in the gene expression pattern
with insulin or IGF-1 treatment for 24 hr. Table 3, 4 show
the up- and down-regulated expression with insulin and IGF-
6 hr 12 hr 24 hr 48 hr
Clustering group 1 Myotrophin Cytochrome c oxidase, subunit VIIIa Neurogranin
Brain acyl-CoA hydrolase
Carbonyl reductase 1
Clustering group 2 Plysia ras-related homolog A2 Homeodomain-interacting 
Cholecystokinin protein kinase 3
Bone morphogenetic protein 6 Demethyl-Q7
Peptidylprolyl isomerase A Calnexin
Clustering group 3 Apolipoprotine C-III Scavenger receptor 
Mismatch repair protein class B, member
Glucuronidase, beta
Transforming growth factor beta 1 
induced transcript 4
Activity-dependent neuroprotective protein
Endothelin converting enzyme 1
Hydroxyacyl-Coenzyme A dehydrogenase/
3-ketoacyl-Coenzyme A thiolase/enoyl- 
Coenzyme A hydratase, beta subunit
Clustering group 4 Ferritin, heavy polypeptide 1 Phosphate 
cytidylyltrans-
ferase 1, choline, 
alpha isoform
Table 2. Change of gene expression with TSH treatment according to treatment time
Gene names written in the table indicate that at that time expression of the gene was maximized. For example, myotrophin was expressed maximally
at 6 hr after TSH treatment. A clustering group was categorized according to the gene expression pattern by clustering analysis.886 Y.J. Lee, D.J. Park, C.S. Shin, et al.
1, respectively. Genes for actinin, the glucagon receptor, Cca3
protein, brain-enriched guanylate kinase-associated, oroso-
mucoid 1, and bone morphogenetic protein 6 were upregu-
lated more than twofold by IGF-1; genes for vascular endo-
thelial growth factor, tropomyosin isoform 6, synuclein, gam-
ma, ribosomal protein L5, ferredoxin 1, syntaxin 5a, and the
mismatch repair protein were downregulated by more than
half. Insulin upregulated the genes for ras-related GTP-bind-
ing protein raga, casein kinase II, alpha 1 polypeptide, ATPase,
H+ transporting, lysosomal accessory protein 1, tubulin, beta
5, and cholecystokinin, and downregulated genes for calci-
um-independent alpha-latrotoxin receptor homolog 2, and
ribosomal protein L37. 
Comparison of the effects of treatment with TSH, insulin
or IGF-1 on gene expression
We evaluated whether the effects of TSH, insulin and IGF-
1, on thyrocyte proliferation, were active in one pathway or
provided additive effects from other pathways. Therefore, we
compared gene expressions patterns with maximum changes
within 24 hr with TSH, insulin, or IGF-1. Fig. 1 shows the
common genes identified. However, there were no common
genes up- or down-regulated by all three growth factors,
thyrotropin, IGF-1, and insulin.
DISCUSSION
For thyroid cells TSH, through adenylate cyclase activa-
tion and cyclic AMP accumulation, induces both cell prolif-
eration and the expression of differentiation characteristics
(10). TSH contributes to the regulation of thyrocyte differ-
entiation by modulating thyroid gene levels (11). Recently,
a number of genes have been identified that are regulated
by TSH. Genes encoding the sodium iodide symporter (NIS),
pendrin, thyroglobulin, and thyroid transcription factor-1
(TTF-1) are examples of such genes (11).
In our study, cDNA microarray studies have revealed that
a number of genes are modulated by TSH in cultured rat
thyrocytes. TSH has been shown to induce different gene
expression patterns in thyrocytes according to time; the effect
may be maximized within 24 hr and thereafter decreases. In
addition, expression of 27 genes (20.5%) out of 132 showed
Common
symbol
Gene name Ratio
Upregulated
Genes associated with binding
Actinin, alpha 1 Actn1 2.004
Genes associated with catalytic activity
Tyrosine 3-monooxygenase/tryptophan  Ywhae 1.342
5-monooxygenase activation protein, 
epsilon polypeptide
Prolyl 4-hydroxylase alha subunit P4ha1 1.306
Genes associated with signal transducer acitivity
Glucagons receptor Gcgr 2.004
Unclassified
Cca3 protein Cca3 3.331
Brain-enriched guanylate kinase-associated Begain 3.311
Orosomucoid 1 Orm1 2.271
Cyclin D1 Ccnd1 1.985
SEC61, alpha subunit Sec61a 1.948
Deleted in liver cancer 1 Dlc1 1.941
Tumor specific antigen 70 kDa Loc192276 1.803
Secretory carrier membrane protein 3 Scamp3 1.619
Vesicle transport-related RA410 1.538
Neurogenic differentiation 3 Ngn1 1.330
Chymotrypsinogen B Ctrb 1.290
Collagen, type V, alpha 2 Col5a2 1.210
FK506-binding protein 1a Fkbp 1a 1.191
Caldesmon 1 Cald1 1.149
Bone morphogenetic protein 6 Bmp6 2.043
Cathepsin B Ctsb 1.978
Integrin alpha L Itgal 1.651
Table 3. Genes that were up- and downregulated by IGF-1
Common
symbol
Gene name Ratio
Downregulated
Genes associated with binding
Vascular endothelial growth factor Vegf 0.332
Genes associated with catalytic activity
Lysophospholipase 1 Lypla1 0.677
Alanine-glyoxylate aminotransferase Agxt 0.689
S6 kinase Rps6kb1 0.825
Genes associated with defense immunity protein
CD5 antigen Cd5 0.620
Genes associated with transporter activity
Cytochrome P450, 2c37 Cyp2c6 0.616
Potassium voltage-gated channel,  Kcnq5 0.742
KQT-like subfamily, member 5
10-formyltetrahydrofolated dehydrogenase Fthfd 0.805
Unclassified
Tropomyosin isoform 6 Loc286890 0.174
Synuclein, gamma Sncg 0.277
Ribosomal protein L5 Rpl5 0.352
Ferredoxin 1 Fdx1 0.363
Upregulated by 1,25-dihydroxyvitamin D-3 Vdup1 0.395
Syntaxin 5a Stx5a  0.452
Mismatch repair protein Mlh1 0.499
Lymphotoxin B Ltb 0.518
Renin-binding protein Renbp 0.581
Major histocompatibility complex, class II,  Hla-dmb 0.591
DM beta
Outer dense fiber of sperm tails 1 Odf1 0.614
Cysteine-rich protein 3 Csrp3 0.739
Ceruloplasmin Cp 0.762
Tumor protein p53 Tp53 0.763
IGF-1, insulin-like growth factor-1.an increased gene activity, which reached its maximum with-
in 6 hr after TSH treatment; most of these genes had apop-
tosis regulator activity, catalytic activity, or transporter activi-
ty. The increased expression of 87 genes (65.9%) was normal-
ized within 24 hr after TSH treatment; however, the genes
that play a role in catalytic activity or signal transducer activi-
ty showed maximum expression at 48 hr. Most of the genes
(123 of 132 genes, 93.2%) showed increased expression with-
in 24 hr. There were no differences observed in the expres-
sion patterns in comparisons between groups with different
functional activity. 
Genes that were upregulated had expression that was more
than doubled within 24 hr in the majority of cases. Therefore,
our investigation focused on these genes. Of these, genes for
cytochrome c oxidase, subunit VIIIa, activity-dependent neu-
roprotective protein, demethyl-Q 7, acyl-coA oxidase, ATPase
Na+/K+ transporting beta 1 polypeptide, cyclin D1, glucagon
receptor, cholecystokinin, beta subunit, and bone morpho-
genetic protein 6 were upregulated by TSH. Among these
genes, we searched for information on cellular proliferation;
especially among the genes that demonstrated the most up-
and downregulated activity. Bone morphogenetic protein
(BMP), a member of the TGF- superfamily, is well known
as a multifunctional regulator of cell growth, differentiation,
and apoptosis; it plays an important role during development.
It is thought to play a pivotal role in endochondral bone for-
mation (12). BMP-2 and BMP-4 control the expression of
pituitary transcription factors; blockade of these signals results
in arrest of pituitary gland development and absence of all
pituitary endocrine cell types. Therefore, absence of pituitary
TSH results in a dysfunctional thyroid gland (13).
For BMP-6, there is relatively little information; its up-
regulation by TSH may have similar effects on the pituitary
and the thyroid gland. Recently, it has been shown that BMPs
transduce their signals directly through the SMAD family of
proteins; however, they have also been reported to interact
with the MAPK and Erk pathways. In one study, Kraunz et
al. reported that BMP3b and BMP6 were epigenetically inac-
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Common
symbol
Gene name Ratio
Upregulated
Genes associated with binding
Ras-related GTP-binding protein ragA Raga 2.480
Insulin-like growth factor 2 Igf2 1.659
Genes associated with catalytic activity
Casein kinase II, alpha 1 polypeptide Csnk2a1 2.096
Dopa decarboxylase Ddc 1.433
Proteasome subunit, alpha type 2 Psma2 1.368
Genes associated with signal transducer activity
Chemokine orphan receptor 1 Rdc1 1.602
Genes associated with transporter activity
ATPase, H+ transporting,  Atp6s1 3.513
lysosomal accessory protein 1
Cytochrome c oxidase, subunit VIIIa Cox8a 1.228
Unclassified
Tubulin, beta 5 Tubb5 7.075
Cholecystokinin Cck 6.477
Ribosomal protein L31 Rpl31 1.885
Cofilin 1 Cfl1 1.793
Enolase 1, alpha Enl1 1.741
Glucuronidase, beta  Gusb 1.706
Elastase 1 Ela1 1.656
Transmembrane 4 superfamily member 3 Tm4sf3 1.573
SWI/SNF related, matrix associated,  Smarcd2 1.459
actin dependent regulator of chromatin, 
subfamily d, member 2
Nucleobindin Nucb 1.458
Myosin regulatory light chain Mrlcb 1.433
Solute carrier family 4, member 1 Slc4a1 1.413
Peroxisomal multifunctional enzyme type II Hsd17b4 1.387
Demethyl-Q 7 Coq7 1.313
Lectin, galactoside-binding, soluble,  Lgals2 1.241
2 (galectin 2)
Lectin, mannose-binding, 1 Lman1 1.082
Table 4. Genes that were up- and downregulated by insulin
Common
symbol
Gene name Ratio
Downregulated
Genes associated with binding
Eukaryotic translation initiation factor 2B Eif2b 0.782
Genes associated with catalytic activity
Phosphatase and tensin homolog Pten 0.633
Mitochondrial intermediate peptidase Mipep 0.650
Cardiac ankyrin repeat kinase Cark 0.658
Mitogen activated protein kinase kinase 1 Map2k1 0.721
P21(CDKN1A)-activated kinase 2 Pak2 0.756
Phosphatecytidylyltransferase 1, choline,  Pcyt1a 0.793
alpha isoform
Guanidinoacetate methyltransferase Gamt 0.793
Cystathionine beta synthase Cbs 0.811
Prostaglandin I2 synthase Ptgis 0.974
Genes associated with signal transducer
Calcium-independent alpha-latrotoxin receptor  Cirl2 0.454
homolog 2
Thyroid stimulating hormone, receptor Tshr 0.595
Diphtheria toxin receptor Dtr 0.725
Genes associated with transporter activity
Mitochondrial voltage dependent anion  Vdac3 0.545
channel 3
NADH dehydrogenase (ubiquinone) 1 alpha  Ndufa5 0.675
subcomplex 5
Unclassified
Ribosomal protein L37 Rpl37 0.497
Biglycan Bgn 0.515
Mitochondrial ribosomal protein L23 Mrpl23 0.569
Cysteine-rich protein 3 Csrp3 0.622
FERM-domain-containing protein 163SCII Loc257646 0.640
Solute carrier family 7, member 1 Slc7a1 0.686
Vesicle transport-related RA410 0.697
SRY-box containing gene 11 Sox11 0.795
Ribosomal protein L4 Rpl4 0.796
Caveolin 3 Cav3 0.838tivated in lung cancer (14). Suzuki et al. (15) reported that
BMP-2, -4, -6, -7, and TGF- 1 suppressed TSH receptor
mRNA expression in thyrocytes, TSH-induced cAMP syn-
thesis, and TSH-induced IGF-1 expression. They suggested
that an aberrant BMP system present in adenomas might
be involved in the development of thyroid follicular lesions.
From this information we may cautiously infer that BMP6
may play a role via MAPK or Erk pathways in the develop-
ment of thyroid goitrogenesis or carcinogenesis. To confir-
ma further studies on BMP6 are needed. 
Previous reports on the glucagon receptor do not support
a role in the growth of the thyroid even though it is expressed
in the thyroid (16). However, it has been shown that in hypo-
thyroid conditions glucagon receptor mRNA expression is
increased. In addition, hyperthyroidism is associated with
an increase in glucagon-binding sites in rat hepatocytes, and
thyroid hormone has been shown to enhance the lipolytic
response in rat adipocytes to glucagons (17). Increase in glu-
cagon-binding sites leads to activation of the G-protein and
elevation of cyclic AMP levels in target tissue. Therefore, it
is possible that this gene may play a role in thyroid prolifer-
ation via the cyclic AMP- protein kinase A pathway (18). 
Cholecystokinin (CCK) has been shown to exert a stimu-
latory effect on follicular thyroid cells manifested by an in-
creased epithelium/colloid volume fraction ratio (19). Appli-
cation of selective antagonists of CCK receptor subtypes has
demonstrated that CCK acts through the CCK1 receptor
subtype at the level of pituitary TSH. The model of endoge-
nous hormone action reveals that thyroid CCK1 is responsi-
ble for thyroid growth. However, to date, functional studies
have failed to demonstrate any convincing effects of cholecys-
tokinin on basal or TSH-stimulated thyroid hormone secre-
tion (20). 
It would be very informative if we could get the expression
of other genes, such as cyclin D1 (21, 22), insulin receptor
substrate 1 (23), c-myc, c-fos, or c-june etc. (6, 24), which
are known to be associated with the growth of thyrocytes,
but unfortunately we could not confirm the expression of
those genes because of insufficient DNA chip information.
It is well known that thyrocyte proliferation is synergisti-
cally activated by TSH and insulin/IGF-1 (4, 6, 25). There-
fore, we investigated differential gene regulation after stim-
ulation with TSH, insulin, and IGF-1. We observed the pres-
ence of a few genes co-regulated by TSH, insulin, or IGF-1.
Genes for bone morphogenetic protein 6, glucagons recep-
tor, and cyclin D1 were upregulated by both TSH and IGF-
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Fig. 1. The genes that were commonly up- and downregulated by TSH, insulin, and IGF-1 are cited in boxes. The number in the diagram
shows the number of genes that were up- or downregulated. The number between the brackets shows the ratio of the genes expressed
in the treated samples compared with control samples. The numbers in brackets are in order: TSH, IGF-1 and insulin. For example, for
Bmp6 (2.061/2.043), 2.061 and 2.043, respectively, are the ratio in the treated samples with TSH and IGF-1 compared with the control. 
Bmp6, bone morphogenetic protein 6; Gcgr, glucagon receptor; Ccnd 1, Cyclin D1; Cyp2c6, cytochrome P450, 2c37; Cck, cholecystokinin;
Gusb, glucuronidase, beta; Coq7, demethyl-Q 7; Cox8a, cytochrome c oxidase, subunit VIIIa; Rpl37, ribosomal protein L37; Rpl4, riboso-
mal protein L4; Csrp3, cystein-rich protein 3; EST, expressed sequence tags.
TSH
Insulin 47 IGF-1
∙Cyp2c6 (0.597/0.616)
∙Similar to APG16L beta isoform (0.739/0.817)
∙Similar to RIKEN cDNA 2300003F07 
(0.536/0.601)
∙Similar to Jtv1-pending protein (0.528/0.521)
∙Others unspecified (two ESTs)
∙Bmp6 (2.061/2.043)
∙Gcgr (1.232/1.445)
∙Ccnd1 (1.616/1.985)
∙Similar to Gpc6 protein (1.990/1.596)
∙Transcribed locus
∙Similar to WS-3 protein (2.162/1.771)
∙Similar to TRS85 homolog (2.394/2.486)
∙Others unspecified (two ESTs)
∙Rpl37 (0.500/0.497)
∙Rpl4 (0.796/0.796)
∙Transcribed locus
∙Cck (2.523/1.304)
∙Gusb (2.005/1.706)
∙Coq7 (1.855/1.313)
∙Cox8a (1.905/1.228)
∙Transcribed locus
∙Csrp3 (0.739/0.622)
55
46
54
0
1
0
0
5
3
9
6
118
1211; the gene for cytochrome P450, 2c37, was downregulated,
by both. In addition, genes for cholecystokinin, glucuroni-
dase, beta, demethyl-Q 7, and cytochrome c oxidase, subunit
VIIIa were upregulated by both TSH and insulin, and genes
for ribosomal protein L37 and ribosomal protein L4 were
downregulated by both growth factors. However, there were
no genes identified that were regulated by all three, TSH,
IGF-1, and insulin.
These findings suggest that TSH, IGF-1, and insulin induce
the proliferation of thyrocytes through distinct signaling
cascades; each plays their respective roles and provides addi-
tional influence on the synergistic regulation of cell prolifer-
ation. Genes for mitogen activated protein kinase 1, thyroid
stimulating hormone receptor, insulin-like growth factor 2
modulated by insulin, and genes for cyclin D1, and vascular
endothelial growth factor modulated by IGF-1 are known
to play a role in thyrocyte growth regulation (21-23). How-
ever, the function of other genes observed to be modulated
by insulin or IGF-1 remains unknown.
For FRTL-5 thyroid cells, a 24-hr pre-incubation with TSH
shortens the G1 phase and strongly amplifies DNA synthe-
sis in response to the addition of insulin or IGF-1 (5). The
continuous presence of TSH is not required during cell cycle
progression triggered and supported by insulin/IGF-1 (4, 25).
A number of investigators (4, 7) have reported that TSH pre-
treatment potentiates IGF-1-dependent tyrosine phosphory-
lation of the insulin receptor substrate (IRS)-2, the activation
of phosphatidylinositol 3-kinase (PI3K), and the phosphory-
lation and upregulation of shc, an adaptor molecule of the
IGF-1 receptor, which activates MAPK pathways. As report-
ed by other investigators (6, 10, 26), triggering of mitogenesis
of thyrocytes by TSH requires the presence of insulin or IGF-
1. All of these findings suggest that TSH, through cAMP,
IGF-1 and insulin, mutually modulate thyrocyte growth. 
In addition, Kimura et al. (6) reported that for FRTL-5
cells the effects of TSH via cAMP exerts potentiating effects
on the PI3K and MAPK pathways activated by insulin/IGF-
1, and suggested that the different relative effects of TSH and
insulin/IGF-1 on the intracellular signaling cascades were
consistent with their relative effects on proliferation. They
(6) also investigated the change of gene expression and report-
ed that genes such as c-myc, cyclin D1, c-fos, and c-june were
stimulated by TSH and also induced by insulin/IGF-1 in
FRTL-5 cells and human thyrocytes. The same findings for
c-fos and c-myc were also reported by Yoo et al. (24). 
In summary, genes increase their expression with TSH and
are activated by insulin or IGF-1, which may result in syn-
ergistic effects on thyrocyte growth by TSH and insulin or
IGF-1.
Our results were insufficient, based on the genetic infor-
mation from the cDNA microarray used, for a clear conclu-
sion. Newer DNA chip technology is superior in quality and
will be used for subsequent studies. In addition, we compared
results with samples treated with TSH and insulin or IGF-1.
However, results for samples treated with insulin or IGF-1
with or without TSH pre-treatment are required for analysis
of a synergistic effect. However, we can conclude that TSH,
insulin, and IGF-1 synergistically and independently induce
cell proliferation.
As noted above, although a number of genes are involved
in thyroid regulation their function is not well-known and
more research is needed to improve our understanding. The
results from this study suggest that TSH, insulin, and IGF-1
have no common signal pathway; these growth factors appear
to have an additive role on the thyroid and complement one
another. 
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